In a new study from Pugatch Consilium consultancy, the U.S. and European economies continue to top the global charts in terms of attractiveness for biopharmaceutical investment. Notwithstanding low costs and considerable potential, emerging markets still come in at the bottom. Canada is also found to be surprisingly low on the list compared to developed economies, mainly due to challenging intellectual property policies. The study, “Measuring the Global Biomedical Pulse: The Biopharmaceutical...